- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04044001
BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
A Prospective Phase Ib/IIa, Active-controlled, Randomized, Open-label Study to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of Multiple Oral Doses of BTZ-043 Tablets in Subjects With Newly Diagnosed, Uncomplicated, Smear-positive, Drug-susceptible Pulmonary Tuberculosis
This is a prospective, open label, two-centre, randomized, controlled, two-stage, phase Ib/IIa study to evaluate the safety, tolerability, PK, drug-drug interaction and bactericidal activity of BTZ-043 administered orally once daily over 14 days to participants with newly diagnosed, uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis.
The primary objective is to assess the safety and tolerability of BTZ-043 given over 14 days by evaluation of adverse events during treatment and follow-up period in patients with newly diagnosed, uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis.
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a prospective, open label, two-centre, randomized, controlled, two-stage, phase Ib/IIa study to evaluate the safety, tolerability, PK, drug-drug interaction and bactericidal activity of BTZ-043 administered orally once daily over 14 days to participants with newly diagnosed, uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis:
Stage 1 is an escalating dose design in up to eight cohorts receiving different doses of BTZ-043 to define a safe dose corridor for BTZ-043. The focus of this stage is on adverse events, PK and a food-effect PK-evaluation .
Stage 2 is a parallel group comparison of 4 arms receiving different treatment regimens: three arms to receive BTZ-043 in different doses within the safe corridor defined in stage 1, compared to one arm receiving Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol as a control. This stage is focusing on adverse effects, early bactericidal activity (EBA), PK and an evaluation of PK drug-drug interaction potential.
A total of up to 77 male and female patients, aged ≥ 18 - 64 years, with newly diagnosed, smear positive, drug sensitive pulmonary tuberculosis will be enrolled.
Allocation of patients will be carried out in two stages:
Stage 1: for each cohort 3 patients will be enrolled, treated and followed-up accordingly, starting with cohort 1. In a Trial Steering Committee (TSC) meeting, decision will be made on the dose in the next cohort.
Dose escalation steps to be followed, if no safety concerns arise:
- Cohort 1: patients to receive 250 mg BTZ-043
- Cohort 2: patients to receive 500 mg BTZ-043
- Cohort 3: patients to receive 750 mg BTZ-043
- Cohort 4: patients to receive 1000 mg BTZ-043
- Cohort 5: patients to receive 1250 mg BTZ-043
- Cohort 6: patients to receive 1500 mg BTZ-043
- Cohort 7: patients to receive 1750 mg BTZ-043
- Cohort 8: patients to receive 2000 mg BTZ-043
Patients receiving the investigational drug in cohorts 1 - 8 will take BTZ-043 in fasting state for 13 days and after a pre-defined high-fat, high-caloric meal on day 14.
After all patients of a current cohort have completed at least 7 days of dosing, the TSC, composed of the national principal investigator (PI), the trial statistician, the sponsor representative and two independent scientists, will review safety data, including clinical, lab and electrocardiography (ECG) data, to assess whether dose limiting toxicity of BTZ-043, as defined below, has been observed in any participant. Depending on the outcome, the TSC will then decide on dose escalation, or on enrolling more participants to the same or a lower dose in the following cohort, according to dose escalation and stopping rules.
After the end of stage 1, the TSC will decide which of the BTZ-043 doses, which are deemed to not exceed the acceptable toxicity level, are to be moved to stage 2.
Stage 2: after the highest possible dose of the investigational drug, that has proven to be safe within the 1st stage, is identified, all remaining patients will be recruited and randomised to receive one of three different doses of BTZ-043 or to control treatment with Rifafour e-275® at a ratio of 3:3:3:2 favouring the experimental treatment.
Stage 2 is focusing on adverse effects, early bactericidal activity (EBA), PK and an evaluation of PK drug-drug interaction potential.
Allocation of patients:
- Arm 1: patients to receive BTZ-043 in a higher dose
- Arm 2: patients to receive BTZ-043 in a medium dose
- Arm 3: patients to receive BTZ-043 in a lower dose
- Control Arm 4: patients to receive Rifafour e-275® as control treatment
Participants will take in BTZ-043 in either fasted or fed state, depending on which state has shown to lead to higher exposure during the 1st stage.
Additional measurements in the 2nd stage in BTZ-arms 1 to 3 only:
• Drug-drug interactions will be investigated: patients, who have been randomized to BTZ-043 arms, will additionally be randomized to receive either a probe drug cocktail, with drugs specifically metabolized by certain enzymes, or dolutegravir at a ratio of 2:1. Probe drugs or Dolutegravir (DTG) will be given pre-BTZ on day 0 and on day 14.
After the course of study drugs is completed (on day 14), all patients (in stage 1 and stage 2) will be referred to a government clinic to complete their course of tuberculosis (TB) according to national standards for a total of 6 months of first-line therapy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Cape Town, South Africa, 7530
- TASK Applied Sciences Clinical Research Centre
-
Cape Town, South Africa, 7700
- University of Cape Town Lung Institute (UCTLI)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
General inclusion criteria:
- Provide written, informed consent prior to all trial-related procedures including HIV testing.
- Understand and willing to comply with the study procedures.
- Male or female adults, aged 18 up to and including 64 years.
- Body weight ≥ 40 kg.
Participants are either unable to conceive/father children AND/OR they will be using two effective methods of contraception, including methods used by the patient's sexual partner(s). At least one to be a barrier method.
Disease-specific inclusion criteria:
- Newly diagnosed, previously untreated, drug-susceptible pulmonary TB
- Chest X-ray which is consistent with TB
- Ability to produce an adequate volume of sputum (at least 10ml estimated overnight production)
- ≥ 1 sputum sample from concentrated sputum positive for acid-fast bacilli on microscopy (at least 1+ on the International Union Against Tuberculosis and Lung Disease/World Health Organization (IUATLD/WHO) scale) from either a spot sputum or overnight sputum sample.
General exclusion criteria:
- Poor general condition, where delay in treatment cannot be tolerated or death within three months is likely, as assessed by the investigator.
The patient is pregnant or breast-feeding.
Disease-specific exclusion criteria:
- The patient is infected with HIV.
- The patient has a known intolerance to any of the study drugs or concomitant disorders or conditions for which study drugs or standard TB treatment are contraindicated.
- Treatment with any other investigational drug within 1 month prior to enrolment or enrolment into other clinical (intervention) trials during participation.
The patient has a history of or current evidence of clinically relevant cardiovascular metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy or any other condition, that will influence treatment response, study adherence or survival in the judgement of the investigator, especially:
- Clinically significant evidence of severe TB (e.g. miliary TB, TB meningitis, excluding limited lymph node involvement)
- Serious lung conditions other than TB or significant respiratory impairment in the discretion of the investigator
- Neuropathy, epilepsy or significant psychiatric disorder
- Any diabetes mellitus
- Cardiovascular disease, such as myocardial infarction, heart failure, coronary heart disease, arrhythmia, tachyarrhythmia, or pulmonary hypertension
- Current or history of hypertension (systolic blood pressure >135 mmHg and/or diastolic blood pressure of >85 mmHg) AND/OR ever received antihypertensive treatment)
- Long QT syndrome or family history of long QT syndrome or sudden death of unknown or cardiac-related cause
- Alcohol or other drug abuse, that is sufficient to significantly compromise the safety or cooperation of the patient, includes substances prohibited by the protocol, or has led to significant organ damage, at the discretion of the investigator
Laboratory exclusion criteria at screening:
- Serum amino aspartate transferase (AST) and/or alanine aminotransferase (ALT) activity >2x the upper limit of normal (ULN)
- serum alkaline phosphatase (ALP) or y-glutamyl transferase (GGT) > 2x the ULN
- serum total bilirubin level >1.5 times the ULN
- estimated creatinine clearance (eCrCl) using the Cockcroft and Gault formula level lower than 60 mls/min
- haemoglobin level <8.0 g/dL
- platelet count <100,000/mm3
serum potassium below the lower level of normal (LLN) for the laboratory
ECG-specific exclusion criteria:
- corrected QT interval (QTc)F of > 450 milliseconds (ms)
- Atrioventricular (AV) block with PR interval > 200 ms
- QRS complex > 120 ms
any other changes in the ECG that are clinically relevant as per discretion of the investigator
Restricted medication:
- Treatment with drugs active against Mycobacterium Tuberculosis (MTB) within the last 3 months prior to screening
Requires medication as included in the following drug classes within 2 weeks prior to the first dose of study treatment:
- medication that prolongs the QTc interval
- Cytochrome P450 (CYP450) inhibitors or inducers, including grapefruit containing foods / beverages and St. John's Wort
- Antacids or antipeptic drugs (antacids, H2 blockers, proton pump inhibitors)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Stage 1 - Cohort 1 (BTZ 250)
Patients will receive 1 tablet of BTZ-043 orally once daily, containing 250mg BTZ-043 from Day 1 through to Day 14
|
BTZ-043 (250mg per tablet)
|
Experimental: Stage 1 - Cohort 2 (BTZ 500)
Patients will receive 2 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (500 mg in total) from Day 1 through to Day 14
|
BTZ-043 (250mg per tablet)
|
Experimental: Stage 1 - Cohort 3 (BTZ 750)
Patients will receive 3 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (750 mg in total) from Day 1 through to Day 14
|
BTZ-043 (250mg per tablet)
|
Experimental: Stage 1 - Cohort 4 (BTZ 1000)
Patients will receive 4 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1000 mg in total) from Day 1 through to Day 14
|
BTZ-043 (250mg per tablet)
|
Experimental: Stage 1 - Cohort 5 (BTZ 1250)
Patients will receive 5 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1250 mg in total) from Day 1 through to Day 14
|
BTZ-043 (250mg per tablet)
|
Experimental: Stage 1 - Cohort 6 (BTZ 1500)
Patients will receive 6 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1500 mg in total) from Day 1 through to Day 14
|
BTZ-043 (250mg per tablet)
|
Experimental: Stage 1 - Cohort 7 (BTZ 1750)
Patients will receive 7 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1750 mg in total) from Day 1 through to Day 14
|
BTZ-043 (250mg per tablet)
|
Experimental: Stage 1 - Cohort 8 (BTZ 2000)
Patients will receive 8 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (2000 total) from Day 1 through to Day 14
|
BTZ-043 (250mg per tablet)
|
Experimental: Stage 2 - Arm 1 (BTZ high)
Patients will receive a higher dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14.
The dose of BTZ-043 will be determined after review of safety data from stage 1.
|
BTZ-043 (250mg per tablet)
A probe drug cocktail will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally. The probe drug cocktail consists of
1 tablet à 50mg Dolutegravir will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally.
Other Names:
|
Experimental: Stage 2 - Arm 2 (BTZ medium)
Patients will receive a medium dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14.
The dose of BTZ-043 will be determined after review of safety data from stage 1.
|
BTZ-043 (250mg per tablet)
A probe drug cocktail will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally. The probe drug cocktail consists of
1 tablet à 50mg Dolutegravir will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally.
Other Names:
|
Experimental: Stage 2 - Arm 3 (BTZ low)
Patients will receive a lower dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14.
The dose of BTZ-043 will be determined after review of safety data from stage 1.
|
BTZ-043 (250mg per tablet)
A probe drug cocktail will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally. The probe drug cocktail consists of
1 tablet à 50mg Dolutegravir will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally.
Other Names:
|
Active Comparator: Stage 2 - Arm 4 (control)
Patients will receive a standard dose of Rifafour e-275® orally once daily according to body weight from Day 1 through to Day 14. Each tablet of Rifafour e-275® contains 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide and 275mg ethambutol. The daily doses will be given to fasting patients, in accordance with South African Guidelines for treatment of TB. The total number of tablets will be based on the body weight at screening:
|
Rifafour e-275® (150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, 275 mg ethambutol per tablet)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of BTZ-043
Time Frame: Day 1 to Day 22
|
Safety and tolerability of BTZ-043 will be assessed by evaluation of Adverse Events (AEs) during treatment- and follow-up phase
|
Day 1 to Day 22
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bactericidal Activity Endpoint - MGIT
Time Frame: Day -1 to Day 14
|
• changes in time to detection in the Mycobacteria Growth Indicator Tube (MGIT™) liquid media culture system from baseline
|
Day -1 to Day 14
|
Bactericidal Activity Endpoint - CFU
Time Frame: Day -1 to Day 14
|
• changes in solid media colony forming units (CFU) from baseline
|
Day -1 to Day 14
|
Bactericidal Activity Endpoint - LAM
Time Frame: Day -1 to Day 14
|
• changes in sputum lipoarabinomannan (LAM) concentration from baseline
|
Day -1 to Day 14
|
Bactericidal Activity Endpoint - MBLA
Time Frame: Day -1 to Day 14
|
• changes in sputum molecular bacterial load assay (MBLA) from baseline
|
Day -1 to Day 14
|
Pharmacokinetic Endpoint - BTZ-043 - AUC
Time Frame: Day 1, 12 and 14
|
The PK of BTZ-043 and its two major metabolites BTZ-045S and M2 after a single dose and at steady state will be evaluated by measuring the area under the plasma concentration curve (AUC)
|
Day 1, 12 and 14
|
Pharmacokinetic Endpoint - BTZ-043 - Cmax
Time Frame: Day 1, 12 and 14
|
The PK of BTZ-043 and its two major metabolites BTZ-045S and M2 after a single dose and at steady state will be evaluated by measuring the observed maximum concentration (Cmax)
|
Day 1, 12 and 14
|
Pharmacokinetic Endpoint - BTZ-043 - Tmax
Time Frame: Day 1, 12 and 14
|
The PK of BTZ-043 and its two major metabolites BTZ-045S and M2 after a single dose and at steady state will be evaluated by measuring the time to reach Cmax (Tmax)
|
Day 1, 12 and 14
|
Pharmacokinetic Endpoint - BTZ-043 - Cmin
Time Frame: Day 1, 12 and 14
|
The PK of BTZ-043 and its two major metabolites BTZ-045S and M2 after a single dose and at steady state will be evaluated by measuring the minimum observed plasma concentration 24 hours following the last dose (Cmin)
|
Day 1, 12 and 14
|
Pharmacokinetic Endpoint - BTZ-043 - Cl
Time Frame: Day 1, 12 and 14
|
The PK of BTZ-043 and its two major metabolites BTZ-045S and M2 after a single dose and at steady state will be evaluated by measuring the Clearance (Cl)
|
Day 1, 12 and 14
|
Pharmacokinetic Endpoint - BTZ-043 - Vd
Time Frame: Day 1, 12 and 14
|
The PK of BTZ-043 and its two major metabolites BTZ-045S and M2 after a single dose and at steady state will be evaluated by measuring the Volume of distribution (Vd)
|
Day 1, 12 and 14
|
Pharmacokinetic Endpoint - BTZ-043 - T1/2
Time Frame: Day 1, 12 and 14
|
The PK of BTZ-043 and its two major metabolites BTZ-045S and M2 after a single dose and at steady state will be evaluated by measuring the Elimination half-life (T1/2)
|
Day 1, 12 and 14
|
Pharmacokinetic Endpoint - BTZ-043 - pharmacodynamics (PD)
Time Frame: Day 1, 12 and 14
|
The PK of BTZ-043 and its two major metabolites BTZ-045S and M2 after a single dose and at steady state will be evaluated by measuring the Relation of efficacy measurements to pharmacokinetic indices of BTZ-043 and its metabolites (AUC, Cmax)
|
Day 1, 12 and 14
|
Pharmacokinetic Endpoint - Population PK AUC
Time Frame: Day 1, 12 and 14
|
A population PK-analysis of BTZ-043 and its two major metabolites will be carried out by measuring the AUC and describing PK differences of BTZ-043 and its main metabolites between subjects to quantify inter-individual variability, suitable for evaluation of alternative dosing regimens
|
Day 1, 12 and 14
|
Pharmacokinetic Endpoint - Population PK Cmax
Time Frame: Day 1, 12 and 14
|
A population PK-analysis of BTZ-043 and its two major metabolites will be carried out by measuring the Cmax and describing PK differences of BTZ-043 and its main metabolites between subjects to quantify inter-individual variability, suitable for evaluation of alternative dosing regimens
|
Day 1, 12 and 14
|
Pharmacokinetic Endpoint - Food Effect PK AUC
Time Frame: Day 14
|
The effect of food on the exposure of the BTZ-043 and its two major metabolites will be determined by measuring the AUC of BTZ-043 and its main metabolites and by evaluating the change after a high fat high calorie meal in comparison to the AUC under fasting conditions during the 1st stage.
|
Day 14
|
Pharmacokinetic Endpoint - Food Effect PK Cmax
Time Frame: Day 14
|
The effect of food on the exposure of the BTZ-043 and its two major metabolites will be determined by measuring the Cmax of BTZ-043 and its main metabolites and by evaluating the change after a high fat high calorie meal in comparison to the Cmax under fasting conditions during the 1st stage.
|
Day 14
|
Pharmacokinetic Endpoint - Probe Drugs PK AUC
Time Frame: Day 0 and 14
|
The effect on BTZ-043 at steady state on hepatic enzyme and P-glycoprotein activity (induction vs. inhibition) will be evaluated by measuring changes in AUC of the probe drugs administered on day 0, and day 14 during the 2nd stage.
|
Day 0 and 14
|
Pharmacokinetic Endpoint - Probe Drugs PK Cmax
Time Frame: Day 0 and 14
|
The effect on BTZ-043 at steady state on hepatic enzyme and P-glycoprotein activity (induction vs. inhibition) will be evaluated by measuring changes in Cmax of the probe drugs administered on day 0, and day 14 during the 2nd stage.
|
Day 0 and 14
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Michael Hoelscher, Prof, University Hospital, LMU Munich, Division of Infectious Diseases and Tropical Medicine
- Principal Investigator: Andreas Diacon, Prof, TASK Applied Science Clinical Research Centre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Tuberculosis
- Tuberculosis, Pulmonary
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antimetabolites
- Hypolipidemic Agents
- Lipid Regulating Agents
- Anti-Bacterial Agents
- HIV Integrase Inhibitors
- Integrase Inhibitors
- Antitubercular Agents
- Fatty Acid Synthesis Inhibitors
- Dolutegravir
- Isoniazid
- Pyrazinamide
- Ethambutol
Other Study ID Numbers
- PanACEA-BTZ-043-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Tuberculoses
-
Centre Hospitalier Universitaire de NiceCompleted
-
Jae-Joon YimNot yet recruitingTuberculosis, Pulmonary | Pulmonary TuberculosesKorea, Republic of
-
Médecins Sans Frontières, FranceHarvard Medical School (HMS and HSDM); Institute of Tropical Medicine, Belgium and other collaboratorsCompletedTuberculosis, Multidrug-Resistant | Infection, Bacterial | Pulmonary TuberculosesPakistan, Georgia, India, Kazakhstan, Lesotho, Peru, South Africa
-
Assiut UniversityCompletedPulmonary Tuberculoses | Pulmonary Function; Newborn, AbnormalEgypt
-
Assiut UniversityCompleted
-
Research Institute of Epidemiology, Microbiology...Active, not recruitingAspergillosis | Pulmonary Tuberculoses | Old Tuberculosis | Active Tuberculosis | Chronic Pulmonary AspergillosisUzbekistan
-
Yonsei UniversityWithdrawnPulmonary Tuberculoses | Treatment Failure | High Risk Factors for Relapse
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Medecins Sans Frontieres, NetherlandsLondon School of Hygiene and Tropical Medicine; University of Liverpool; Ministry... and other collaboratorsRecruitingMulti-drug Resistant Tuberculosis | Pulmonary Tuberculoses | Extensively Drug-Resistant TuberculosisBelarus, South Africa, Uzbekistan
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
Clinical Trials on BTZ-043
-
Michael HoelscherLeibniz Institute for Natural Product Research and Infection Biology Hans...CompletedLung Diseases | Mycobacterium Infections | Tuberculosis | Tuberculosis, Pulmonary | Bacterial Infections RespiratoryNetherlands
-
Michael HoelscherGerman Federal Ministry of Education and Research; German Center for Infection... and other collaboratorsCompletedLung Diseases | Bacterial Infections | Mycobacterium Infections | Tuberculosis | Tuberculosis, PulmonaryGermany
-
GlaxoSmithKlineClick-TB ConsortiumRecruiting
-
Adverum Biotechnologies, Inc.Completed
-
Michael HoelscherRadboud University Medical Center; University College, London; University of...RecruitingTuberculosis, Pulmonary | Other Specified Pulmonary TuberculosisSouth Africa, Tanzania
-
Adverum Biotechnologies, Inc.CompletedAlpha 1-Antitrypsin DeficiencyUnited States
-
GreenLight Biosciences, Inc.Withdrawn
-
M.D. Anderson Cancer CenterWyeth is now a wholly owned subsidiary of PfizerCompletedLeukemia | Chronic Myeloid Leukemia | Chronic Myelogenous LeukemiaUnited States
-
Michael HoelscherRadboud University Medical Center; University College, London; University of...RecruitingPulmonary Tuberculosis | Other Specified Pulmonary TuberculosisGabon, South Africa, Tanzania, Malawi, Uganda, Mozambique
-
University College, LondonLondon School of Hygiene and Tropical Medicine; Radboud University Medical... and other collaboratorsRecruitingPulmonary TuberculosisSouth Africa